Related Experiment Videos
Controlled trial of two different methylprednisolone doses in cadaveric renal transplantation
Abstract:
In a controlled trial the effects of two different methylprednisolone (MP) schedules were studied in 100 cadaver kidney adult recipients followed for 18-46 months. Group A patients were given 160 mg/day i.v. for 3 days, then oral MP (0.8 mg/kg/day), which was tapered by 4 mg/week to a maintenance dose of 16 mg/day up to the 6th month. Group B patients were given 80 mg/day i.v. for 3 days followed by 0.4 mg/kg/day oral MP; the dose was reduced by 2 mg/week to 16 mg/day. In both groups, the dose was further reduced bimonthly to a final dose of 8 mg/day. No significant differences were evidenced between the two groups in patients and kidney survival or in the incidence of complications. The number of patients with at least one rejection episode was significantly higher in the lower dose group.
Insights
Two methylprednisolone dosing regimens in kidney transplant recipients showed similar survival rates. However, the lower dose schedule resulted in a higher incidence of rejection episodes, impacting kidney transplant outcomes.
Area of Science:
- Nephrology
- Immunosuppression
- Transplantation
Background:
- Methylprednisolone (MP) is a corticosteroid used in kidney transplantation.
- Optimizing MP dosing is crucial for balancing efficacy and side effects.
- Controlled trials are needed to compare different MP administration schedules.
Purpose of the Study:
- To compare the efficacy and safety of two different methylprednisolone (MP) dosing regimens in adult cadaver kidney recipients.
- To evaluate the impact of varying MP doses on patient and graft survival, rejection rates, and complications.
Main Methods:
- A controlled trial involving 100 adult cadaver kidney recipients.
- Two groups received different IV and oral methylprednisolone (MP) schedules with distinct tapering protocols.
- Patients were followed for 18-46 months post-transplantation.
Main Results:
- No significant differences were observed in patient survival, kidney survival, or overall complication incidence between the two MP groups.
- The group receiving the lower methylprednisolone (MP) dose exhibited a significantly higher number of patients experiencing at least one rejection episode.
- Graft survival and patient survival were comparable across both dosing strategies.
Conclusions:
- While lower-dose methylprednisolone (MP) may not significantly increase overall complications or decrease survival rates in kidney transplant recipients, it is associated with a higher risk of rejection.
- Careful consideration of MP dosing is necessary to mitigate rejection risk while managing immunosuppression.
- Further research may explore personalized MP regimens to optimize outcomes in kidney transplantation.